Latest "Zenobia Therapeutics" News Stories - Page: 4

09:51 EDT 18th June 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 76–100 of 6,300+

Probably Relevant

Third Rock Ventures Launches Cedilla Therapeutics to Target Protein Stability Using Small Molecule Therapeutics

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Rock Ventures. Cedilla is leveraging a growing understanding of the principles that dictate protein stability and appl...

Appointments: Gilead, Shield Therapeutics, Gelesis, TG Therapeutics, Aziyo Biologics, Allogene Therapeutics, Mesoblast and CGT Catapult Make New Hires

Latest appointments announced by pharma and biotech firms.      

Osiris Therapeutics (OSIR) and Jazz Pharmaceuticals (JAZZ) Critical Comparison

Osiris Therapeutics and Jazz Pharmaceuticals are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations. Osiris Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Rubius raises $100m funding to further support red-cell therapeutics development

US-based biotechnology company Rubius Therapeutics has raised $100m crossover financing to further support manufacturing and clinical development of red-cell therapeutics.

TapImmune agrees to merge with Marker Therapeutics

US-based immunotherapies company TapImmune has signed a definitive merger agreement to buy multi-antigen T-cell therapy platform developer Marker Therapeutics. The...Read More... The post TapImmune agrees to merge with Marker Therapeutics appeared first on Pharmaceutical Technology.

Pear Therapeutics closes $50mm Series B round

Pear Therapeutics Inc. (prescription digital therapeutics) closed a $50mm Series B financing round led by Temasek, which join...

Novartis, Pear co-develop digital therapeutics for MS and schizophrenia

Novartis AG and Pear Therapeutics Inc. are together developing candidates from Pear's prescription digital therapeutics pipel...

#news #biotech Nektar Therapeutics reportedly considering a sale

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Nektar Therapeutics reportedly considering a sale .Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a Bloomberg report that it is exploring … Continue reading → Cet article #news #biotech Nektar Therapeutics reportedly...

iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations

iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.

Phase III miss wipes 60% off VBL Therapeutics share price

Shares in Nasdaq-listed VBL Therapeutics collapsed today after the Modiin, Israel-based oncology specialist…

Spark Therapeutics, Inc.: Spark Therapeutics geht Lizenzierungs- und Liefervereinbarung für das Prüfpräparat Voretigene Neparvovec außerhalb der USA ein

Novartis Pharmaceuticals wird das Prüfpräparat Voretigene Neparvovec nach erfolgter Zulassung in Europa und allen anderen Märkten außerhalb der USA vermarkten; Spark Therapeutics behält die gewerb...

United Therapeutics to acquire SteadyMed

United Therapeutics Corp. is paying $4.46 per share in cash (a 55% premium) to acquire SteadyMed Ltd. United Therapeutics wil...

Capricor Therapeutics, Inc.: Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018

LOS ANGELES, CA / ACCESSWIRE / April 6, 2018 / Capricor Therapeutics (NASDAQ: CAPR) today announces that AJ Bergmann, Chief Financial Officer will be a featured presenter at the MicroCap Conference...

Magenta’s Bastiano Sanna Appointed Semma Therapeutics CEO

Bastiano Sanna has been named CEO and president of Semma Therapeutics. Elizabeth Stoner, who has been serving as interim CEO, will remain as an advisor to the company. Sanna comes to Cambridge, MA-based Senna from Magenta Therapeutics, where he was chief operating officer. His experience also includes positions at Novartis (NYSE: NVS). Semma is developing […]

LifeArc and the Milner Therapeutics Institute Will Use AI to Find New Drug Targets

LifeArc and the Milner Therapeutics Institute have partnered up to use AI to find and test drug targets for cancer and respiratory diseases. LifeArc, a medical research charity in the UK, and the Milner Therapeutics Institute at Cambridge University have ... This awesome article LifeArc and the Milner Therapeutics Institute Will Use AI to Find New Drug Targets appeared first on Be ki...

Spark Therapeutics, Inc.: Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 20, 2018, at 8...

Alnylam and Sanofi Enter Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global d...

Evox Therapeutics expands into new facilities at Oxford Science Park

The exosome therapeutics company announced the expansion will enhance its research and development capabilities and will facilitate its growth

Vectalys, Flashcell Merge to Form New Gene Therapy Company

Flash Therapeutics to develop RNA-based therapeutics and provide broad lentiviral development and manufacturing services

Capricor Therapeutics initiates HOPE-2 trial in US

Capricor Therapeutics has initiated the HOPE-2 clinical trial of CAP-1002 to treat patients with advanced stages of Duchenne muscular dystrophy,...Read More... The post Capricor Therapeutics initiates HOPE-2 trial in US appeared first on Drug Development Technology.

JW Therapeutics brings in $90mm through Series A round

JW Therapeutics (Shanghai) Co. Ltd. (cell-based immunotherapies for cancer) raised $90mm through its Series A round. Investor...

Specialists Rethink Lung Cancer Treatment Plans, With Eye On IO Biomarkers

Plenary speaker at this year's meeting, Leena Gandhi, envisioned a future where individual patients receive a precisely defined immunotherapy regimen.   

Arcturus Therapeutics Announces Expansion of Collaboration with...

Arcturus Therapeutics Ltd. , a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited . Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis and other gastrointestinal related disorders using Arcturus's wholly-owned LUNA...

Rapidly-growing Nektar Therapeutics reportedly considering sale of its business

After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 billion and Sanofi’s spending spree to acquire Bioverativ for $11.6 billion and Ablynx for $4.8 billion, many in the industry are asking who will be the next to make a deal. Whoever decides to splash the cash next, it could be to pick up Nektar Therapeutics, who is reported ...

Alexion bids $855m for rare disease biotech Wilson Therapeutics

Alexion wants to buy Swedish rare diseases biotech Wilson Therapeutics for around $855 million, which is developing a late-stage drug to treat the inherited condition Wilson Disease. In a statement Wilson Therapeutics’ board said it unanimously re...

Quick Search


News Quicklinks